Cochrane Abstracts
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Edited (no change to conclusions)
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Edited (no change to conclusions) is a topic covered in the Cochrane Abstracts.
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin Edited (no Change to Conclusions)." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435472/all/Cilostazol_versus_aspirin_for_secondary_prevention_of_vascular_events_after_stroke_of_arterial_origin_Edited__no_change_to_conclusions_. Accessed 08 April 2020.
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Edited (no change to conclusions). Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435472/all/Cilostazol_versus_aspirin_for_secondary_prevention_of_vascular_events_after_stroke_of_arterial_origin_Edited__no_change_to_conclusions_. Accessed April 8, 2020.
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Edited (no change to conclusions). In Cochrane Abstracts Retrieved April 08, 2020, from https://evidence.unboundmedicine.com/evidence/view/Cochrane/435472/all/Cilostazol_versus_aspirin_for_secondary_prevention_of_vascular_events_after_stroke_of_arterial_origin_Edited__no_change_to_conclusions_
Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin Edited (no Change to Conclusions) [Internet]. In: Cochrane Abstracts. [cited 2020 April 08]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435472/all/Cilostazol_versus_aspirin_for_secondary_prevention_of_vascular_events_after_stroke_of_arterial_origin_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin Edited (no change to conclusions)
ID - 435472
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435472/all/Cilostazol_versus_aspirin_for_secondary_prevention_of_vascular_events_after_stroke_of_arterial_origin_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -